SCHEDULE: Armistice Capital Boosts Kura Oncology Stake to 5.37%

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5.37% in Kura Oncology, Inc., holding 4,672,000 shares as of September 30, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Kura Oncology, Inc.
• The Reporting Persons beneficially own 4,672,000 shares of Kura Oncology, Inc.'s Common Stock.
• This ownership represents 5.37% of the total class of securities outstanding.
• The shares outstanding used for this calculation are 87,017,518, as reported by Kura Oncology, Inc. in its Form 10-Q filed on November 4, 2025, as of October 31, 2025.
• Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a significant institutional investor maintaining a stake above 5% can be seen as a vote of confidence. The filing explicitly states the shares were acquired in the ordinary course of business and not for control, which reduces immediate concerns about activist pressure.

Positives

• A significant institutional investor, Armistice Capital, maintains a substantial stake, indicating continued confidence in Kura Oncology, Inc.
• The filing confirms that the shares are held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist intent to influence control.

Risks

• The concentration of a significant portion of shares (5.37%) in the hands of a single institutional investor and its managing member could lead to potential volatility if the investor decides to significantly alter its position.
• While the filing states no intent to influence control, a large stake always carries the potential for future influence on corporate governance or strategic decisions.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from Kura Oncology, Inc. It primarily reports the current beneficial ownership stake of Armistice Capital, LLC and Steven Boyd.

Industry Context

Kura Oncology, Inc. operates in the biotechnology sector, specifically focusing on oncology. The disclosure of a significant institutional stake by Armistice Capital, a hedge fund, is a common occurrence in the biotech industry, where investment firms often take positions in companies with promising drug pipelines. Such filings provide transparency into major institutional holdings, which can be viewed as a vote of confidence or a strategic investment in the company's future prospects within the competitive oncology landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Armistice Capital may be viewed positively, signaling institutional confidence in Kura Oncology, Inc. This could potentially influence investor sentiment and trading activity.
• Management: Awareness of a large institutional holder may influence management's strategic decisions, even if the filing states no intent to influence control.

Key Dates

Recommendation

The filing indicates a significant institutional investor, Armistice Capital, maintains a substantial stake in Kura Oncology, Inc. This suggests continued institutional interest and confidence. However, a Schedule 13G filing primarily provides ownership transparency and does not offer new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The 'hold' recommendation reflects the stability implied by a major investor's continued position without new catalysts for significant upward or downward re-evaluation based solely on this ownership disclosure.

Keywords

Kura Oncology, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Oncology, Investment Management